Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma

被引：0
作者：
Ji Hyun Lee
Sung-Hyun Kim
Hye Ryeon Kim
Chang-Ki Min
Je-Jung Lee
Ho-Jin Shin
Jae-Cheol Jo
Ji Yun Lee
Joon Ho Moon
Kihyun Kim
机构：
[1] Dong-A University College of Medicine,Department of Internal Medicine
[2] The Catholic University of Korea,Department of Hematology, Seoul St. Mary’s Hematology Hospital, College of Medicine
[3] Chonnam National University Medical School,Department of Hematology
[4] Pusan National University Hospital,Oncology, Chonnam National University Hwasun Hospital
[5] University of Ulsan College of Medicine,Division of Hematology
[6] Seoul National University Bundang Hospital,Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute
[7] Kyungpook National University,Department of Hematology and Oncology, Ulsan University Hospital
[8] Sungkyunkwan University School of Medicine,Department of Internal Medicine
[9] Samsung Medical Center,Division of Hematology
来源：
International Journal of Hematology | 2023年 / 117卷
关键词：
Ixazomib; Lenalidomide; Real-world; Asia; Relapsed; Refractory; Multiple myeloma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 235
页数：10
相关论文
共 137 条
[1]  
van de Donk N(2021)Multiple myeloma Lancet 397 410-427
[2]  
Pawlyn C(2015)Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 372 142-152
[3]  
Yong KL(2016)Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma N Engl J Med 374 1621-1634
[4]  
Stewart AK(2016)Daratumumab, lenalidomide, and dexamethasone for multiple myeloma N Engl J Med 375 1319-1331
[5]  
Rajkumar SV(2015)Elotuzumab therapy for relapsed or refractory multiple myeloma N Engl J Med 373 621-631
[6]  
Dimopoulos MA(2020)Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and Ird Expert Rev Hematol 13 421-433
[7]  
Masszi T(2019)Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 pts from the insight MM global, prospective Observat Study Blood 134 1887-562
[8]  
Spicka I(2021)Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: a multicenter retrospective analysis Eur J Haematol 106 555-4700
[9]  
Oriol A(2011)Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2 Blood 117 4696-e346
[10]  
Moreau P(2016)International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol 17 e328-S53
12345678910